Добро пожаловать
Нажатие «Авторизоваться» означает, что вы соглашаетесь с Условия использования и политика конфиденциальности Cointime.
Зарегистрировать аккаунт
Аккаунт уже существует?
Нажатие «page.Sign up» означает, что вы соглашаетесь с <a class="underline" href="#term-of-service">Условия использования</a> и a class="underline" href="#privacy-policy">политика конфиденциальности</a> Cointime.
Войдите, используя email
Зарегистрируйтесь с помощью email
твой почтовый ящик
Проверь свои входящие
Нажмите на ссылку в , чтобы войти.
Нажмите на ссылку в , чтобы зарегистрироваться.
PetDx
company
About
PetDx is a molecular diagnostics company dedicated to the detection and treatment of cancer in pets.
- 51 - 100
Highlights
Details
- Last Funding Type
- Series B
- Last Funding Money Raised
- $62M
- Industries
- Biotechnology,Health Diagnostics,Life Science,Pet,Veterinary
- Founded date
- Jan 1, 2019
- Number Of Employee
- 51 - 100
- Operating Status
- Active
PetDx® – The Liquid Biopsy Company for Pets is a San Diego-based molecular diagnostics company dedicated to unleashing the power of genomics to improve pet health. The company's flagship product, OncoK9®, enables veterinarians to detect cancer in dogs with a simple blood draw. As a first-in-class multi-cancer early detection (MCED) test, OncoK9 employs cutting-edge genomic analysis that leverages next-generation sequencing (NGS) technology and proprietary bioinformatics algorithms, empowering veterinarians to provide superior care to canine patients.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
$72M
PetDx has raised a total of
$72M
in funding over 2 rounds. Their latest funding was raised on
Dec 9, 2021 from a Series B round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Dec 9, 2021 | Series B | $62M | 1 | — | — | Detail |
| Jun 1, 2020 | Series A | $10M | 1 | — | — | Detail |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
